Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 2/20 | 0.53 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.53 |
| ▸ | NR3C1 | P04150 | 8/20 | 0.41 |
| ▸ | PGR | P06401 | 2/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.41 |
| ▸ | AR | P10275 | 2/20 | 0.41 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL520862 | 0.86 | KEAP1 (0.44) | KEAP1NFE2L2NR3C1PGRNR3C2 | |
| SCHEMBL29782337 | 0.85 | BTK (0.40) | KEAP1NFE2L2CA12CA1CA2 | |
| SCHEMBL17699534 | 0.85 | BTK (0.40) | KEAP1NFE2L2CA12CA1CA2 | |
| SCHEMBL21929104 | 0.84 | KEAP1 (0.41) | KEAP1NFE2L2NR3C1PGRNR3C2 | |
| SCHEMBL15649276 | 0.84 | KEAP1 (0.41) | KEAP1NFE2L2NR3C1PGRNR3C2 | |
| SCHEMBL31562239 | 0.83 | KEAP1 (0.40) | KEAP1NFE2L2NR3C1PGRNR3C2 | |
| SCHEMBL17699913 | 0.80 | JAK2 (0.38) | CA12CA1CA2CA3CA4 | |
| SCHEMBL20293692 | 0.78 | LIPE (0.39) | JAK2BTKNPC1RAB9A | |
| SCHEMBL12602971 | 0.78 | JAK2 (0.38) | CA12CA1CA2CA3CA4 | |
| SCHEMBL31381519 | 0.77 | JAK2 (0.39) | CA12CA1CA2CA3CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021486-B2 | Coumarin-like cyclic compound as MEK inhibitor and use thereof | CSTONE PHARMACEUTICALS (KY) | 2021-06-01 | — | — | US | disclosed |
| EP-3643308-B1 | COUMARIN-LIKE CYCLIC COMPOUND AS MEK INHIBITOR AND USE THEREOF | CSTONE PHARMACEUTICALS (KY) | 2021-05-19 | — | — | EP | disclosed |
| WO-2020125747-A1 | CRYSTAL FORM AND AMORPHOUS FORM OF MEK INHIBITOR AND APPLICATIONS THEREOF | 基石药业（苏州）有限公司 | 2020-06-25 | — | — | WO | disclosed |
| US-20200148695-A1 | COUMARIN-LIKE CYCLIC COMPOUND AS MEK INHIBITOR AND USE THEREOF | CSTONE PHARMACEUTICALS (KY) | 2020-05-14 | — | — | US | disclosed |
| EP-3643308-A1 | COUMARIN-LIKE CYCLIC COMPOUND AS MEK INHIBITOR AND USE THEREOF | CSTONE PHARMACEUTICALS (KY) | 2020-04-29 | — | — | EP | disclosed |
| US-20090149445-A1 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | COGHLAN MICHAEL JOSEPH | 2009-06-11 | — | — | US | disclosed |
| US-7411072-B2 | Tricyclic steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2008-08-12 | — | — | US | disclosed |
| US-7411072-B2 | Tricyclic steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2008-08-12 | — | — | US | disclosed |
| US-7411072-B2 | Tricyclic steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2008-08-12 | — | — | US | disclosed |
| US-20060063759-A1 | Tricyclic steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY | 2006-03-23 | — | — | US | disclosed |
| EP-1519915-A2 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-04-06 | — | — | EP | disclosed |
| WO-2004052847-A2 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-06-24 | — | — | WO | disclosed |
| WO-2004052847-A2 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11021486-B2 | Coumarin-like cyclic compound as MEK inhibitor and use thereof | MAP3K11, MAP3K15, MAP3K20 | KEAP1 82/4885NFE2L2 815/4885NR3C1 3654/4885 |
| US-20090149445-A1 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | NR5A1, NR3C2, NR3C1 | KEAP1 1196/4885NFE2L2 496/4885NR3C1 3/4885 |
| US-20200148695-A1 | COUMARIN-LIKE CYCLIC COMPOUND AS MEK INHIBITOR AND USE THEREOF | MAP3K11, MAP3K15, MAP3K20 | KEAP1 82/4885NFE2L2 815/4885NR3C1 3654/4885 |
| US-20060063759-A1 | Tricyclic steroid hormone nuclear receptor modulators | NR5A1, NR3C2, NR3C1 | KEAP1 1265/4885NFE2L2 564/4885NR3C1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.